Back to today’s briefing

Story perspectives

Genmab Acquires Merus for $8 Billion in Cancer Deal

9/29/2025

26 4 Full Breakdown

Summary

Story summary

Genmab A/S will acquire Merus NV for $8 billion in cash at $97 per share, a 41% premium to September 26 close.
Merus NV develops treatments for head and neck cancer and advanced bowel cancer in Phase 3 trials.
The deal will be financed partly with $5.5 billion of debt.
Merus will be delisted from Nasdaq after unanimous board approvals.

1 of 1

Story summary

Genmab A/S will acquire Merus NV for $8 billion in cash at $97 per share, a 41% premium to September 26 close.
Merus NV develops treatments for head and neck cancer and advanced bowel cancer in Phase 3 trials.
The deal will be financed partly with $5.5 billion of debt.
Merus will be delisted from Nasdaq after unanimous board approvals.